8-KMaterial AgreementsExhibits & Filings

AbbVie Inc. 8-K Report, Material Agreement (May 12, 2016)

Filed May 12, 2016For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed an 8-K on May 12, 2016, detailing a significant debt financing transaction. The company entered into an Underwriting Agreement on May 9, 2016, to issue and sell a substantial aggregate principal amount of senior notes across various maturities. This includes $1.8 billion in 2.300% senior notes due 2021, $1 billion in 2.850% senior notes due 2023, $2 billion in 3.200% senior notes due 2026, $1 billion in 4.300% senior notes due 2036, and $2 billion in 4.450% senior notes due 2046, totaling $7.8 billion in new debt. This issuance was conducted under a previously filed shelf registration statement. The filing also includes the execution of Supplemental Indenture No. 3 with U.S. Bank National Association as trustee, formalizing the terms of these new debt securities. Investors should view this as a strategic move by AbbVie to secure long-term funding, likely for general corporate purposes, potential acquisitions, or research and development initiatives, leveraging favorable market conditions for debt issuance.

Key Highlights

  • 1AbbVie issued $7.8 billion in senior notes across five different maturities (2021, 2023, 2026, 2036, and 2046).
  • 2The interest rates on the notes range from 2.300% for the shortest maturity (2021) to 4.450% for the longest maturity (2046).
  • 3The debt issuance was conducted through an Underwriting Agreement with a syndicate of major underwriters led by Barclays Capital Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, and Merrill Lynch, Pierce, Fenner & Smith Incorporated.
  • 4The notes were issued under AbbVie's existing shelf registration statement filed with the SEC in April 2015.
  • 5A Supplemental Indenture was executed with U.S. Bank National Association, acting as trustee, to govern the terms of these newly issued debt securities.
  • 6The filing includes exhibits such as the Underwriting Agreement, the Supplemental Indenture, and opinions from legal counsel.
  • 7The Chief Financial Officer, William J. Chase, signed the filing, indicating its financial significance.

Frequently Asked Questions

This 8-K filing announces AbbVie's entry into a material definitive agreement for the issuance and sale of $7.8 billion in senior notes. It details the principal amounts, interest rates, and maturities of these notes, signifying a significant debt financing transaction.

AbbVie is issuing a total of $7.8 billion in senior notes. This includes $1.8 billion of 2.300% notes due 2021, $1 billion of 2.850% notes due 2023, $2 billion of 3.200% notes due 2026, $1 billion of 4.300% notes due 2036, and $2 billion of 4.450% notes due 2046.

This issuance significantly increases AbbVie's long-term debt. The funds raised are likely intended for general corporate purposes, which could include funding research and development, potential acquisitions, or refinancing existing debt. Investors should assess the company's ability to manage this increased debt load and the strategic use of the proceeds.

More detailed information can be found in the exhibits filed with this 8-K, including the Underwriting Agreement (Exhibit 1.1) and the Supplemental Indenture No. 3 (Exhibit 4.1). Forms of the specific notes are also included within Exhibit 4.1, and legal opinions are provided in Exhibits 5.1 and 23.1.